CTOs on the Move

Flower One

www.flowerone.com

 
Flower One is the largest cannabis cultivator, producer, and full-service brand fulfillment partner in the state of Nevada. By combining more than 20 years of greenhouse operational excellence with best-in-class cannabis operators, Flower One offers consistent, reliable, and scalable fulfillment to a growing number of industry-leading cannabis brands (Cookies, Kiva, Old Pal, Heavy Hitters, Lift Ticket`s, The Clear, and Flower One`s leading in-house brand, NLVO, and more). Flower One currently produces a wide range of products from flower, full-spectrum oils, and distillates to finished consumer packaged goods, including a variety of: pre-rolls, concentrates, edibles, topicals, and more for the top-performing ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.flowerone.com
  • 3950 North Bruce Street
    Las Vegas, NV USA 89030
  • Phone: 702.623.2919

Executives

Name Title Contact Details

Funding

Flower One raised $20.8M on 11/17/2019
Flower One raised $39M on 10/07/2020

Similar Companies

Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation`s leading ophthalmology outsourcing facility and pharmaceutical compounding business.

Spinal Elements

Spinal Elements, Inc. is an innovative spine technology company that delivers new standards in spine surgery. Spinal Elements, previously Amendia.

Promius Pharma

Promius Pharma is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.

Become io

io is a biotechnology company that focuses on improving the quality of protein and overall nutrition through advanced Ingredient Optimized technology. They improve powders and supplements used in food production, transforming the performance of protein...